Please assess the completion status of the following clinical trial:

Trial Title: GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 8-19 years old~* Subject able to give assent, and parent/guardian capable of giving consent on behalf of the child~* Body mass index (BMI) ≥ 99th percentile (based on gender and age)~Exclusion Criteria:~* Type 1 or 2 diabetes mellitus~* Initiation of a new drug therapy within the past 30 days prior to the screening visit~* BMI ≥ 55~* History of weight loss surgery~* Obesity from a genetic cause (e.g., Prader-Willi)~* Central nervous system injury or severe neurological impairment~* Known systolic or diastolic dysfunction or heart failure~* Females who are currently pregnant or planning to become pregnant~* Liver enzymes \> 2.5 times upper limit of normal~* Severe renal impairment (defined as creatinine clearance \<30 mL/min)~* Gastrointestinal disease

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): Exenatide
- Control (Type: NO_INTERVENTION): Control - no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).